JOHNSON & JOHNSON $88.35

up +0.34


21/5/2013 03:21 PM  |  NYSE : JNJ  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
12 Mo. Price Change : 39% - JNJ has outperformed the S&P 500 by 10%

Get Trend Analysis Icon Get Trend Analysis

ETF Alternatives sponsored by



People viewing JNJ also viewed: , , , ,

Competitors

Ticker Name Volume % Change
ARNI ARNO THERAPEUTICS 7.5K +0.56%
AVXT AVAX TECHNOLOGIES 12.0K +0.39%
BMGP BIOGMAGNETICS DIAGNOSITCS 562.5K +0.39%
SETS RG GLOBAL LIFESTYLES 12.3K +0.37%
PXSLY PHARMAXIS 100.0 +0.36%
View All

JNJ Stock Analysis

  1.

    Roche, Reloaded

    (RHHBY,BMY,GILD,MRK,JNJ )
    Roche has one of the best long-term growth profiles in the Big Pharma space
  2.

    Little Left To Dendreon But The Hope Trade

    (DNDN,JNJ,MDVN )
    Dendreon looks increasingly irrelevant as the medical community moves on from Provenge.
  3.

    Recent Financials May Not Be Entirely Fair To Hologic

    (HOLX,BDX,QGEN,GE,JNJ,PHG )
    Macro pressures are outweighing solid internal progress at Hologic.
  4.

    In A Growth-Starved Sector, Becton Dickinson Rules

    (BDX,JNJ,HSP,FMS,MDT )
    Becton Dickinson is a great business, but investors seem to be too willing to overpay for today's relatively stronger growth.

  5. It Gets A Little Harder From Here For Covidien

    (COV,JNJ,SYK,BCR,MDT,CSII,ISRG,CNMD,ABT )
    Expectations are the bigger issue for Covidien, as underlying growth is still pretty good on a relative basis.

  6. Kimberly-Clark Looks Way Too Expensive For What It Is

    (KMB,PG,UN,CL,JNJ )
    Kimberly-Clark's growth prospects make today's valuation hard to justify.

  7. Is Controversy About Robot-Assisted Surgery Showing In Intuitive Surgical's Numbers?

    (ISRG,COV,JNJ,SYK,MAKO )
    Uncertainty about procedure growth may be opening a window in these often-expensive shares
  8.

    Broad Weakness Makes It Harder To Like St. Jude Today

    (STJ,BSX,MDT,EW,JNJ,ATRC )
    Although I do believe the long-term expectations for St. Jude are increasingly beatable, this could be a frustrating stock to own for a little while yet.
Free Reports
  1.

    Forbes Quant Model: 3 Top Stocks

    Using Forbes’ exclusive Quant Model, we’ve chosen three stocks that we think could double in price in the next 12 months.
  2.

    Stock Ideas From Warren Buffett

    Access Coattail Investor’s latest free report and get two investing ideas from Warren Buffett himself!
  3.

    3 Stocks Peter Lynch Would Buy Today

    This new special report identifies 3 stocks based on Lynch’s market-trouncing strategy that could more than double in the next 12 months.
Marketplace
Trading Center